GF Fund Management CO. LTD. Sells 46,110 Shares of Hims & Hers Health, Inc. $HIMS

GF Fund Management CO. LTD. lessened its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 38.3% in the third quarter, HoldingsChannel reports. The fund owned 74,404 shares of the company’s stock after selling 46,110 shares during the period. GF Fund Management CO. LTD.’s holdings in Hims & Hers Health were worth $4,220,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of HIMS. Virtus Advisers LLC acquired a new stake in Hims & Hers Health in the 2nd quarter worth about $26,000. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Quaker Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $29,000. Bessemer Group Inc. boosted its stake in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health during the first quarter worth approximately $30,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HIMS has been the subject of several analyst reports. Barclays initiated coverage on Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Bank of America decreased their target price on shares of Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, February 9th. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, KeyCorp assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $39.32.

Insider Transactions at Hims & Hers Health

In other news, COO Michael Chi sold 13,750 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares in the company, valued at approximately $11,202,460.31. This represents a 4.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 9,067 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the sale, the chief financial officer directly owned 91,617 shares in the company, valued at approximately $2,779,659.78. This trade represents a 9.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 129,337 shares of company stock valued at $4,651,648. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Trading Up 3.2%

HIMS opened at $16.31 on Friday. The company has a market cap of $3.71 billion, a P/E ratio of 30.21, a PEG ratio of 3.04 and a beta of 2.43. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The company’s 50 day moving average is $30.86 and its 200-day moving average is $41.98. Hims & Hers Health, Inc. has a 1-year low of $15.63 and a 1-year high of $72.98.

Hims & Hers Health declared that its Board of Directors has initiated a share repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to buy up to 3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.